162 related articles for article (PubMed ID: 31448875)
1. MRI characteristics predict the efficacy of meloxicam treatment in patients with desmoid-type fibromatosis.
Shimizu K; Hamada S; Sakai T; Ito S; Urakawa H; Arai E; Ikuta K; Koike H; Ishiguro N; Nishida Y
J Med Imaging Radiat Oncol; 2019 Dec; 63(6):751-757. PubMed ID: 31448875
[TBL] [Abstract][Full Text] [Related]
2. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
Hamada S; Futamura N; Ikuta K; Urakawa H; Kozawa E; Ishiguro N; Nishida Y
PLoS One; 2014; 9(5):e96391. PubMed ID: 24788118
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.
Sakai T; Nishida Y; Hamada S; Koike H; Ikuta K; Ota T; Ishiguro N
Diagn Pathol; 2017 Aug; 12(1):66. PubMed ID: 28851389
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of cultured desmoid cells with different CTNNB1 mutation status.
Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
[TBL] [Abstract][Full Text] [Related]
5. Nuclear expression of β-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors.
Hamada S; Urakawa H; Kozawa E; Futamura N; Ikuta K; Shimoyama Y; Nakamura S; Ishiguro N; Nishida Y
Tumour Biol; 2014 May; 35(5):4561-6. PubMed ID: 24390670
[TBL] [Abstract][Full Text] [Related]
6. Multifocal occurrence of extra-abdominal desmoid type fibromatosis - A rare manifestation. A clinicopathological study of 6 sporadic cases and 1 hereditary case.
Bekers EM; van Broekhoven DLM; van Dalen T; Bonenkamp JJ; van der Geest ICM; de Rooy JWJ; van Gorp JM; Creytens DH; de Leng WWJ; Scheijen B; Eijkelenboom A; Flucke U
Ann Diagn Pathol; 2018 Aug; 35():38-41. PubMed ID: 29705714
[TBL] [Abstract][Full Text] [Related]
7. Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).
Kasper B; Gruenwald V; Reichardt P; Bauer S; Hohenberger P; Haller F
Ann Surg Oncol; 2016 Jun; 23(6):1924-7. PubMed ID: 26861905
[TBL] [Abstract][Full Text] [Related]
8. Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status.
Nishida Y; Tsukushi S; Urakawa H; Hamada S; Kozawa E; Ikuta K; Ando Y; Ishiguro N
Int J Clin Oncol; 2015 Dec; 20(6):1211-7. PubMed ID: 25899770
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI.
Ingley KM; Burtenshaw SM; Theobalds NC; White LM; Blackstein ME; Gladdy RA; Thipphavong S; Gupta AA
Cancer Med; 2019 Sep; 8(11):5047-5057. PubMed ID: 31301110
[TBL] [Abstract][Full Text] [Related]
10. Differential diagnosis and mutation stratification of desmoid-type fibromatosis on MRI using radiomics.
Timbergen MJM; Starmans MPA; Padmos GA; Grünhagen DJ; van Leenders GJLH; Hanff DF; Verhoef C; Niessen WJ; Sleijfer S; Klein S; Visser JJ
Eur J Radiol; 2020 Oct; 131():109266. PubMed ID: 32971431
[TBL] [Abstract][Full Text] [Related]
11. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study.
Colombo C; Miceli R; Lazar AJ; Perrone F; Pollock RE; Le Cesne A; Hartgrink HH; Cleton-Jansen AM; Domont J; Bovée JV; Bonvalot S; Lev D; Gronchi A
Cancer; 2013 Oct; 119(20):3696-702. PubMed ID: 23913621
[TBL] [Abstract][Full Text] [Related]
12. Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study.
Koike H; Nishida Y; Kohno K; Shimoyama Y; Motoi T; Hamada S; Kawai A; Ogose A; Ozaki T; Kunisada T; Matsumoto Y; Matsunobu T; Ae K; Gokita T; Sakai T; Shimizu K; Ishiguro N
Hum Pathol; 2019 Feb; 84():155-163. PubMed ID: 30292627
[TBL] [Abstract][Full Text] [Related]
13. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
[TBL] [Abstract][Full Text] [Related]
14. Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.
Verschoor AJ; Cleton-Jansen AM; Wijers-Koster P; Coffin CM; Lazar AJ; Nout RA; Rubin BP; Gelderblom H; Bovée JV
Am J Surg Pathol; 2015 Dec; 39(12):1701-7. PubMed ID: 26414222
[TBL] [Abstract][Full Text] [Related]
15. Correlation between tumor growth and hormonal therapy with MR signal characteristics of desmoid-type fibromatosis: A preliminary study.
Gondim Teixeira PA; Chanson A; Verhaeghe JL; Lecocq S; Louis M; Hossu G; Blum A
Diagn Interv Imaging; 2019 Jan; 100(1):47-55. PubMed ID: 30037746
[TBL] [Abstract][Full Text] [Related]
16. Desmoid fibromatosis: MRI features of response to systemic therapy.
Sheth PJ; Del Moral S; Wilky BA; Trent JC; Cohen J; Rosenberg AE; Temple HT; Subhawong TK
Skeletal Radiol; 2016 Oct; 45(10):1365-73. PubMed ID: 27502790
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis.
Zanchetta E; Ciniselli CM; Bardelli A; Colombo C; Stacchiotti S; Baldi GG; Provenzano S; Bertulli R; Bini F; Casale A; Greco FG; Ferrari A; Verderio P; Fiore M; Gronchi A; Casali PG; Morosi C; Palassini E
Cancer Med; 2021 Jul; 10(13):4356-4365. PubMed ID: 34102009
[TBL] [Abstract][Full Text] [Related]
18. Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of
Mir O; Honoré C; Chamseddine AN; Dômont J; Dumont SN; Cavalcanti A; Faron M; Rimareix F; Haddag-Miliani L; Le Péchoux C; Levy A; Court C; Briand S; Fadel E; Mercier O; Bayle A; Brunet A; Ngo C; Rouleau E; Adam J; Le Cesne A
Clin Cancer Res; 2020 Dec; 26(23):6277-6283. PubMed ID: 32873570
[TBL] [Abstract][Full Text] [Related]
19. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool.
Amary MF; Pauwels P; Meulemans E; Roemen GM; Islam L; Idowu B; Bousdras K; Diss TC; O'Donnell P; Flanagan AM
Am J Surg Pathol; 2007 Sep; 31(9):1299-309. PubMed ID: 17721184
[TBL] [Abstract][Full Text] [Related]
20. Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).
Kummar S; O'Sullivan Coyne G; Do KT; Turkbey B; Meltzer PS; Polley E; Choyke PL; Meehan R; Vilimas R; Horneffer Y; Juwara L; Lih A; Choudhary A; Mitchell SA; Helman LJ; Doroshow JH; Chen AP
J Clin Oncol; 2017 May; 35(14):1561-1569. PubMed ID: 28350521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
